DePuy Synthes Separates From Johnson & Johnson
ESTIMATEDDate confidence: ESTIMATEDA target, not a fixed dateHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all ESTIMATED pins71% CONFIDENCEOverall confidence: 71%How well the pin's source and references back up its dates.Weighted average of how firmly 5 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins from 50% to 74% confidencein 272 daysJ&J's 10-Q for the quarter to 28 June 2026 targets "completion within 18 to 24 months after the initial announcement" of 14 October 2025 (mid-April to mid-October 2027), and CFO Joseph Wolk said in July that J&J "is on track for a mid-2027 separation" (Bloomberg); "mid-2027" is read as the middle of the year, 1 July 2027, which sits inside that window.[1]
Johnson & Johnson's orthopaedics business is due to leave the group as DePuy Synthes - by tax-free spinoff or by sale, with Apollo in talks at about $20 billion - and J&J says it is on track for a mid-2027 separation.
